SPIReL: PHASE 2 STUDY DPX-SURVIVAC WITH INTERMITTENT LOW DOSE CYCLOPHOSPHAMIDE AND PEMBROLIZUMAB IN PATIENTS WITH RECURRENT/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

Authors :: Neil L. Berinstein
Gail Klein
Nancy Pennell
K. Roos-Assar
I.A. Bence-Buckler
Douglas A. Stewart
Liam Smyth
Pierre Laneuville
C. Kerr
Source :: Hematological Oncology. 37:569-569
Publication Year :: 2019
Publisher :: Wiley, 2019.

Subjects :: Cancer Research
medicine.medical_specialty
business.industry
Phases of clinical research
Hematology
General Medicine
Pembrolizumab
Gastroenterology
DPX-Survivac
Oncology
Internal medicine
medicine
Refractory Diffuse Large B-Cell Lymphoma
In patient
Low dose cyclophosphamide
business

Full Text Access

Tools